Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

A machine learning tool incorporating both clinical and genomic data helps predict response to CDK4/6 inhibitor therapy in ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type ...

A new once-a-day tablet that treats advanced breast cancer is to be rolled out on the NHS, with about 1,100 patients in ...

Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the ...

The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK -positive locally advanced or metastatic ...

The Food and Drug Administration has approved Ensacove for patients with ALK-positive locally advanced or metastatic ...

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small ...